Record mula sa primary source
MateryalNaisumite ang aplikasyon
Ina-update ng Avidity Biosciences ang Timeline ng BLA Submission para sa del-zota sa Q1 2026
Ina-update ng Avidity Biosciences ang inaasahang timing para sa BLA submission ng del-zota sa unang quarter ng 2026. Ang pagbabagong ito mula sa nakaraang gabay na katapusan ng taon 2025 ay upang payagan ang pagbibigay ng karagdagang non-clinical data upang suportahan ang CMC package para sa submission.
Mahahalagang fact
- Na-file
- Okt 14, 2025, 01:30 PM
- Kaganapan
- Naisumite ang aplikasyon
- Direksyon
- Neutral
- Kumpanya
RNAAtrium Therapeutics- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
rna-20251013 0001599901 FALSE 0001599901 2025-09-09 2025-09-09 0001599901 2025-10-13 2025-10-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 8-K _________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 13, 2025 _________________________________________ AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) _________________________________________ Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 3020 Callan Road San Diego , California 92121 92121 (Address of